CinCor Pharma, Inc.

Big multibillion-dollar merger-and-acquisition deals have been few and far between in 2025, but that does not mean dealmaking has come to a standstill. In fact, based on Scrip ’s interviews and obser

Now that AstraZeneca’s oral PCSK9 inhibitor AZD0780 has successfully navigated a Phase IIb trial, attention can now shift to baxdrostat, a second cardiovascular candidate the UK firm believes can have

Mineralys reported data from a pair of clinical trials for lorundrostat (MLS-101) in uncontrolled or resistant hypertension on 10 March that it asserts could provide a new treatment option for about 1

The biopharmaceutical industry has been through a tremendous period of company creation, and even with a drop in financings during 2022 and 2023 from record levels of funding in 2020 and 2021, the las